Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proto Labs transforms CAD files into real parts in days, but understanding how those rapid-fire orders translate into revenue, cash flow, and insider sentiment isn’t nearly as quick. The company’s 10-K spans hundreds of pages on injection-molding capacity, 3-D printing utilization, and CNC expansion plans—details analysts can’t afford to miss.
Stop combing through dense disclosures. Stock Titan delivers AI-powered summaries that break down every Proto Labs SEC filing—whether it’s a Proto Labs annual report 10-K simplified or a Proto Labs quarterly earnings report 10-Q filing. Need real-time alerts? Our engine flags Proto Labs Form 4 insider transactions real-time, highlights option exercises, and answers the search most professionals type: “Proto Labs insider trading Form 4 transactions.” Material events like new plant openings arrive as they happen, with Proto Labs 8-K material events explained in plain English.
Here’s what you can do in minutes instead of hours:
- Trace segment margins across printing, molding, and machining with Proto Labs earnings report filing analysis.
- Monitor Proto Labs executive stock transactions Form 4 before product-launch cycles.
- Compare pay packages via the Proto Labs proxy statement executive compensation dashboard.
- Ask natural questions like “understanding Proto Labs SEC documents with AI” and get instant answers.
All filings, one workspace—10-K, 10-Q, 8-K, S-8, DEF 14A, ownership forms, and more—updated straight from EDGAR the moment they post. Stock Titan’s expert analysis translates complex manufacturing metrics into actionable insights so you can focus on decisions, not documents.
Proto Labs Inc. Chief Operations Officer reported an amended insider transaction involving company common stock. On November 25, 2025, the officer exercised 3,048 employee stock options at an exercise price of $33.84 per share, receiving the same number of common shares. That same day, the officer sold 3,048 common shares at a weighted average price of $50.1741 per share under a pre-established Rule 10b5-1 trading plan adopted on August 15, 2025. After these transactions, the officer beneficially owned 28,898 common shares directly. The filing also clarifies that the stock options were fully vested and corrects the stated expiration date of the options to February 14, 2026, fixing a clerical error in a prior report while leaving all other transaction details unchanged.
Proto Labs, Inc. (PRLB)11/25/2025, the officer exercised an employee stock option for 3,048 shares of common stock at an exercise price of $33.84 per share, then sold 3,048 shares of common stock in open-market transactions at a weighted average price of $50.1741 per share. After these transactions, the officer directly beneficially owned 28,898 shares of Proto Labs common stock and held 4,664 employee stock options following the reported exercise. The filing notes that the trades were made under a Rule 10b5-1 trading plan adopted on August 15, 2025, and that the ownership total includes 57 shares acquired through the company’s employee stock purchase plan.
Proto Labs (PRLB)695 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $34,686.76 and an approximate sale date of 11/25/2025.
The 695 shares were acquired on 05/14/2024 through an Employee Stock Purchase Plan and paid for in cash. The filing also reports that during the past three months, Ryaboy sold 9,710 common shares on 11/07/2025 for gross proceeds of $471,629.27. By signing the notice, he represents that he is not aware of any undisclosed material adverse information about Proto Labs.
Proto Labs (PRLB)
The seller acquired the 3,048 shares on 11/25/2025 by exercising stock options granted by the issuer and paid the purchase price in cash on the same date. The Form 144 also includes the standard representation that the seller does not know of any undisclosed material adverse information about Proto Labs’ current or prospective operations.
Proto Labs, Inc. (PRLB)3,718 shares of common stock as a restricted stock unit grant at a price of $0, increasing direct beneficial ownership to 3,718 shares. The filing also reports a grant of an employee stock option for 6,818 shares of common stock with a $47.07 exercise price, expiring on 11/17/2035.
The restricted stock units vest annually over four years starting on November 15, 2026, and the stock option vests on the same schedule. This structure is designed so that the officer earns the awards gradually over time, which can help align long-term incentives with company performance and retention.
Disciplined Growth Investors, Inc. filed Amendment No. 6 to a Schedule 13G reporting beneficial ownership of 2,592,373 Proto Labs (PRLB) common shares, representing 10.9% of the class as of 09/30/2025.
The filer reports sole voting power over 2,316,889 shares and sole dispositive power over 2,592,373 shares, with no shared voting or dispositive power. The reporting person is classified as an investment adviser (IA).
In its certification, the filer states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Proto Labs.
PRLB filed a Form 144 for a proposed sale of 9,710 common shares, with an aggregate market value of $471,629.27. The shares may be sold through Morgan Stanley Smith Barney LLC, with an approximate sale date of 11/07/2025 on the NYSE. The securities were acquired primarily via restricted stock vesting under a registered plan and an employee stock purchase plan, including tranches such as 1,567 shares vested on 02/13/2024 and 797 shares purchased on 11/15/2023.
Proto Labs (PRLB) reported Q3 2025 results. Revenue rose to
Growth was led by the U.S. segment, where revenue increased
Year-to-date revenue reached
Proto Labs, Inc. (PRLB) furnished an 8-K announcing its third quarter 2025 financial results. The company reported the news via a press release that is attached to the filing as Exhibit 99.1 and incorporated by reference.
The filing is administrative in nature and points readers to the press release for the full results.
Proto Labs (PRLB)Chief Technology & AI Officer and indicated no securities are beneficially owned.
The filing was made by one reporting person and includes a Power of Attorney as an exhibit.
FAQ
What is the current stock price of Proto Labs (PRLB)?
What is the market cap of Proto Labs (PRLB)?
